Basiliximab therapy for immune-mediated bowel disease in a pediatric heart transplant patient.

Autor: Kiskaddon AL; Department of Pharmacy, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.; Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Balitmore, Marlyand, USA., Wilsey M; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA., Gonzalez-Gomez I; Division of Pathology, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA., Laks J; Heart Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA., Miles A; Department of Pharmacy, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA., Carapellucci J; Heart Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA., Asante-Korang A; Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Balitmore, Marlyand, USA.; Heart Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.
Jazyk: angličtina
Zdroj: Pediatric transplantation [Pediatr Transplant] 2023 Mar; Vol. 27 (2), pp. e14443. Date of Electronic Publication: 2022 Nov 23.
DOI: 10.1111/petr.14443
Abstrakt: In pediatric patients who undergo heart transplantation, severe immune-mediated bowel disease has been reported. Management is complex, and there are little data discussing the use of basiliximab for immune-mediated bowel disease. This case report discusses a pediatric patient who developed immune-mediated bowel disease following heart transplantation and was successfully managed with basiliximab.
(© 2022 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje